{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:58:25Z","timestamp":1782417505220,"version":"3.54.5"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Genzyme Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ymgme.2025.109294","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T17:35:43Z","timestamp":1763660143000},"page":"109294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Focused ultrasound delivery of enzyme replacement therapy to the brain of Gaa\u2212\/\u2212 Pompe disease mice"],"prefix":"10.1016","volume":"147","author":[{"given":"Paige","family":"Nowlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Chrisholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernie Simone","family":"Owusu-Yaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Bali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaymin","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.ymgme.2025.109294_bb0005","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2200587","article-title":"In utero enzyme-replacement therapy for infantile-onset Pompe\u2019s disease","volume":"387","author":"Cohen","year":"2022","journal-title":"N Engl J Med"},{"issue":"9646","key":"10.1016\/j.ymgme.2025.109294_bb0010","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ymgme.2025.109294_bb0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.21037\/atm.2019.04.15","article-title":"Challenges in treating Pompe disease: an industry perspective","volume":"7","author":"Do","year":"2019","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109294_bb0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"Alpha-glucosidase deficiency in generalized glycogenstorage disease (Pompe\u2019s disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem J"},{"issue":"5","key":"10.1016\/j.ymgme.2025.109294_bb0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.ymgme.2025.109294_bb0030","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.20019","article-title":"Enzyme replacement therapy in late-onset Pompe\u2019s disease: a three-year follow-up","volume":"55","author":"Winkel","year":"2004","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109294_bb0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid \u03b1-glucosidase","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109294_bb0040","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","article-title":"Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study","volume":"39","author":"van Gelder","year":"2016","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109294_bb0045","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ymgme.2011.10.012","article-title":"Early cognitive development in children with infantile Pompe disease","volume":"105","author":"Spiridigliozzi","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"13","key":"10.1016\/j.ymgme.2025.109294_bb0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.21037\/atm.2019.04.49","article-title":"An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond","volume":"7","author":"Korlimarla","year":"2019","journal-title":"Ann Transl Med"},{"issue":"10","key":"10.1016\/j.ymgme.2025.109294_bb0055","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1007\/s00415-010-5618-0","article-title":"Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease","volume":"257","author":"Sacconi","year":"2010","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109294_bb0060","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1148\/radiol.2202001804","article-title":"Noninvasive MR imaging\u2013guided focal opening of the blood-brain barrier in rabbits","volume":"220","author":"Hynynen","year":"2001","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109294_bb0065","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41598-018-36340-0","article-title":"Blood-brain barrier opening in primary brain tumors with non-invasive MR-guided focused ultrasound: a clinical safety and feasibility study","volume":"9","author":"Mainprize","year":"2019","journal-title":"Sci Rep"},{"issue":"30","key":"10.1016\/j.ymgme.2025.109294_bb0070","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ymgme.2025.109294_bb0075","doi-asserted-by":"crossref","first-page":"14018","DOI":"10.1038\/mtm.2014.18","article-title":"Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease","volume":"1","author":"Wang","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ymgme.2025.109294_bb0080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.omtm.2019.11.020","article-title":"Comparisons of infant and adult mice reveal age effects for liver depot gene therapy in Pompe disease","volume":"17","author":"Han","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ymgme.2025.109294_bb0085","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","article-title":"Low-dose liver-targeted gene therapy for Pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction","volume":"4","author":"Han","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"10.1016\/j.ymgme.2025.109294_bb0090","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.nmd.2014.12.004","article-title":"Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease","volume":"25","author":"Case","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109294_bb0095","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with Alglucosidase alfa prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr Res"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109294_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.10.010","article-title":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report","volume":"25","author":"Kishnani","year":"2023","journal-title":"Genet Med"},{"key":"10.1016\/j.ymgme.2025.109294_bb0105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1750-1172-8-90","article-title":"Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy","volume":"8","author":"Prater","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109294_bb0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"10.1016\/j.ymgme.2025.109294_bb0115","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/cpdd.1314","article-title":"Pharmacokinetics of Alglucosidase alfa manufactured at the 4000-L scale in participants with Pompe disease: a phase 3\/4 open-label study","volume":"12","author":"Nicolas","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"8","key":"10.1016\/j.ymgme.2025.109294_bb0120","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/NEN.0b013e3181815994","article-title":"Temporal Neuropathologic and behavioral phenotype of 6 neo \/6 neo Pompe disease mice","volume":"67","author":"Sidman","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"10.1016\/j.ymgme.2025.109294_bb0125","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3390\/pharmaceutics16060710","article-title":"Focused ultrasound-mediated disruption of the blood\u2013brain barrier for AAV9 delivery in a mouse model of Huntington\u2019s disease","volume":"16","author":"Owusu-Yaw","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymgme.2025.109294_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117762","article-title":"Characterization of focused ultrasound blood-brain barrier disruption effect on inflammation as a function of treatment parameters","volume":"182","author":"Angolano","year":"2025","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.ymgme.2025.109294_bb0135","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109294_bb0140","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109294_bb0145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1073\/pnas.93.1.65","article-title":"High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease","volume":"93","author":"Van Hove","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ymgme.2025.109294_bb0150","series-title":"The Metabolic and Molecular Basis of Inherited Diseases","first-page":"3389","article-title":"Glycogen storage disease type II: acid alpha glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2000"},{"key":"10.1016\/j.ymgme.2025.109294_bb0155","series-title":"Disorders of the Motor Unit","first-page":"667","article-title":"Definitive assays for glycogen debranching enzyme in human fibroblasts","author":"Brown","year":"1982"},{"key":"10.1016\/j.ymgme.2025.109294_bb0160","series-title":"Congenital Metabolic Diseases","first-page":"227","article-title":"Diagnosis of glycogen storage disease","author":"Brown","year":"1985"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109294_bb0165","first-page":"37","article-title":"Diurnal variability of glucose tetrasaccharide (Glc4) excretion in patients with glycogen storage disease type III","volume":"58","author":"Young","year":"2021","journal-title":"JIMD Rep"},{"issue":"6","key":"10.1016\/j.ymgme.2025.109294_bb0170","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2023.0552","article-title":"Efficacy and safety of Avalglucosidase alfa in patients with late-onset Pompe disease after 97 weeks: a phase 3 randomized clinical trial","volume":"80","author":"Kishnani","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ymgme.2025.109294_bb0175","first-page":"6","article-title":"Pompe disease: from pathophysiology to therapy and back again","author":"Lim","year":"2014","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"10.1016\/j.ymgme.2025.109294_bb0180","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125358","article-title":"Improved efficacy of a next-generation ERT in murine Pompe disease","volume":"4","author":"Xu","year":"2019","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109294_bb0185","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1566523219666190621113807","article-title":"Reduction of Autophagic accumulation in Pompe disease mouse model following gene therapy","volume":"19","author":"McCall","year":"2019","journal-title":"Curr Gene Ther"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109294_bb0190","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymgme.2011.11.005","article-title":"\u03b22 agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease","volume":"105","author":"Koeberl","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"7","key":"10.1016\/j.ymgme.2025.109294_bb0195","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/hum.2018.197","article-title":"Salmeterol with liver depot gene therapy enhances the skeletal muscle response in murine Pompe disease","volume":"30","author":"Han","year":"2019","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ymgme.2025.109294_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010549","article-title":"Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-\u03b2 plaque load in the TgCRND8 mouse model of Alzheimer\u2019s disease","author":"Jord\u00e3o","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2025.109294_bb0205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.expneurol.2013.05.008","article-title":"Amyloid-\u03b2 plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound","volume":"248","author":"Jord\u00e3o","year":"2013","journal-title":"Exp Neurol"},{"key":"10.1016\/j.ymgme.2025.109294_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2020.593672","article-title":"\u0392-Amyloid plaque reduction in the Hippocampus after focused ultrasound-induced blood-brain barrier opening in Alzheimer\u2019s disease","volume":"14","author":"D\u2019Haese","year":"2020","journal-title":"Front Hum Neurosci"},{"issue":"41","key":"10.1016\/j.ymgme.2025.109294_bb0215","doi-asserted-by":"crossref","first-page":"14777","DOI":"10.1073\/pnas.0506892102","article-title":"Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII","volume":"102","author":"Vogler","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ymgme.2025.109294_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114234","article-title":"Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins","volume":"184","author":"Pardridge","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"10.1016\/j.ymgme.2025.109294_bb0225","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/14656566.2025.2491508","article-title":"Improving the treatment of Pompe disease with enzyme replacement therapy: current strategies and clinical evidence","volume":"26","author":"Corsini","year":"2025","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109294_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.108119","article-title":"Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease","volume":"141","author":"Kenney-Jung","year":"2024","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.ymgme.2025.109294_bb0235","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ymgme.2005.03.010","article-title":"Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease","volume":"85","author":"An","year":"2005","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10.1016\/j.ymgme.2025.109294_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00446","article-title":"Neurological glycogen storage diseases and emerging therapeutics","volume":"21","author":"Colpaert","year":"2024","journal-title":"Neurotherapeutics"},{"issue":"4\u20135","key":"10.1016\/j.ymgme.2025.109294_bb0245","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0960-8966(99)00117-0","article-title":"Modulation of disease severity in mice with targeted disruption of the acid \u03b1-glucosidase gene","volume":"10","author":"Raben","year":"2000","journal-title":"Neuromuscul Disord"},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2025.109294_bb0250","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol Genet Metab"},{"issue":"24","key":"10.1016\/j.ymgme.2025.109294_bb0255","doi-asserted-by":"crossref","first-page":"9621","DOI":"10.3390\/ijms21249621","article-title":"Preclinical research in glycogen storage diseases: a comprehensive review of current animal models","volume":"21","author":"Almod\u00f3var-Pay\u00e1","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"23","key":"10.1016\/j.ymgme.2025.109294_bb0260","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ymgme.2025.109294_bb0265","first-page":"2","article-title":"Hypoglossal neuropathology and respiratory activity in Pompe mice","author":"Lee","year":"2011","journal-title":"Front Physiol"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109294_bb0270","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/1570159X21666230810110901","article-title":"The modulation by anesthetics and analgesics of respiratory rhythm in the nervous system","volume":"22","author":"Hao","year":"2024","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109294_bb0275","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ultrasmedbio.2015.10.009","article-title":"Safety validation of repeated blood\u2013brain barrier disruption using focused ultrasound","volume":"42","author":"Kobus","year":"2016","journal-title":"Ultrasound Med Biol"},{"issue":"10","key":"10.1016\/j.ymgme.2025.109294_bb0280","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/mds.29190","article-title":"Putaminal recombinant Glucocerebrosidase delivery with magnetic resonance <scp>\u2212<\/scp> guided focused ultrasound in Parkinson\u2019s disease: a phase I study","volume":"37","author":"Meng","year":"2022","journal-title":"Mov Disord"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225002860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225002860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:26:00Z","timestamp":1771655160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719225002860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1096719225002860"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109294","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Focused ultrasound delivery of enzyme replacement therapy to the brain of Gaa\u2212\/\u2212 Pompe disease mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109294"}}